Sells Galleri, a blood test that screens for many cancers, to patients and healthcare customers.
10-K for FY2025, filed Mar 12, 2026
Screening is the main business: patients and healthcare customers pay for tests, with invoices generally due within 30 days. Biopharmaceutical partners pay for pilot studies as work is completed and for longer development projects as services progress.
10-K for FY2025, filed Mar 12, 2026The Company recognizes screening revenue from the sale of cancer screening testing services for patients. Patients obtain tests via…View ↗
Biopharmaceutical partners engage the Company to run pilot and research studies by sending patient samples and comparing the Company’s test…View ↗
Following favorable results from pilot and research studies, biopharmaceutical partners and the Company may enter into development service…View ↗
10-K for FY2025, filed Mar 12, 2026
FY2025 revenue by product or service ↗$147.2M
10-K for FY2025, filed Mar 12, 2026
$147.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Screening revenue
Sold outright
10-K for FY2025, filed Mar 12, 2026 |
94%
FY2022: 72%
|
Screening revenue, FY2025
$138.6M Sources
|
Sold outright |
|
Development Services
Recurring
|
5.8%
FY2022: 28%
|
Development Services, FY2025
$8.6M Sources
|
Recurring |
Patients obtain tests through healthcare, employer and insurance partners, or directly via telemedicine; biopharmaceutical companies engage GRAIL for development studies.
10-K for FY2025, filed Mar 12, 2026
No. It lost $408.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$103.6MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Jun 1, 2026
In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the…View ↗
Loading...